Combined inhibition of CDK4/6 and AKT is effective in Rb-intact triple-negative breast cancer of the luminal androgen receptor (LAR) subtype

被引：0
|
作者：
Kim, Gun Min
Lee, Kyung-min
Sudhan, Dhivya
Lin, Albert
Marin, Arnaldo
Chatterjee, Sumanta
Ye, Dan
Kandagatla, Vishal
Mendiratta, Saurabh
Hanker, Ariella
Arteaga, Carlos
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-PD3-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD3-07
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Combination of androgen receptor inhibitor enzalutamide with the CDK4/6 inhibitor ribociclib in triple negative breast cancer cells
    Choupani, Edris
    Madjd, Zahra
    Saraygord-Afshari, Neda
    Kiani, Jafar
    Hosseini, Arshad
    PLOS ONE, 2022, 17 (12):
  • [22] The novel potential of palbociclib (CDK4/6 inhibitor) in the treatment of triple-negative breast cancer
    Kashiwagi, Shinichiro
    Asano, Yuka
    Goto, Wataru
    Takada, Koji
    Takashima, Tsutomu
    Morisaki, Tamami
    Noda, Satoru
    Onoda, Naoyoshi
    Hirakawa, Kosei
    Ohira, Masaichi
    CANCER RESEARCH, 2017, 77
  • [23] The novel potential of palbociclib (CDK4/6 inhibitor) in the treatment of triple-negative breast cancer
    Asano, Yuka
    Kashiwagi, Shinichiro
    Goto, Wataru
    Takahashi, Katsuyuki
    Takashima, Tsutomu
    Noda, Satoru
    Onoda, Naoyoshi
    Tomita, Shuhei
    Hirakawa, Kosei
    Ohira, Masaichi
    CANCER RESEARCH, 2017, 77
  • [24] Molecular and Epigenetic Biomarkers in Luminal Androgen Receptor: A Triple Negative Breast Cancer Subtype
    Judes, Gaelle
    Dagdemir, Aslihan
    Karsli-Ceppioglu, Seher
    Lebert, Andre
    Dauplat, Marie-Melanie
    Rifai, Khaldoun
    Daures, Marine
    Dubois, Lucas
    Bignon, Yves-Jean
    Penault-Llorca, Frederique
    Bernard-Gallon, Dominique
    OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY, 2016, 20 (10) : 610 - 613
  • [25] Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition
    Fassl, Anne
    Brain, Christopher
    Abu-Remaileh, Monther
    Stukan, Iga
    Butter, Deborah
    Stepien, Piotr
    Feit, Avery S.
    Bergholz, Johann
    Michowski, Wojciech
    Otto, Tobias
    Sheng, Qing
    Loo, Alice
    Michael, Walter
    Tiedt, Ralph
    DeAngelis, Carmine
    Schiff, Rachel
    Jiang, Baishan
    Jovanovic, Bojana
    Nowak, Karolina
    Ericsson, Maria
    Cameron, Michael
    Gray, Nathanael
    Dillon, Deborah
    Zhao, Jean J.
    Sabatini, David M.
    Jeselsohn, Rinath
    Brown, Myles
    Polyak, Kornelia
    Sicinski, Piotr
    SCIENCE ADVANCES, 2020, 6 (25):
  • [26] Proteomic characterisation of triple negative breast cancer cells following CDK4/6 inhibition
    Melina Beykou
    Mar Arias-Garcia
    Theodoros I. Roumeliotis
    Jyoti S. Choudhary
    Nicolas Moser
    Pantelis Georgiou
    Chris Bakal
    Scientific Data, 9
  • [27] Proteomic characterisation of triple negative breast cancer cells following CDK4/6 inhibition
    Beykou, Melina
    Arias-Garcia, Mar
    Roumeliotis, Theodoros I.
    Choudhary, Jyoti S.
    Moser, Nicolas
    Georgiou, Pantelis
    Bakal, Chris
    SCIENTIFIC DATA, 2022, 9 (01)
  • [28] Dual inhibition of CDK4/6 and IL-6 pathways as a novel therapeutic approach for triple-negative breast cancer cells
    Caroland, Kailey
    Shi, Changyou
    Lo, Hui-Wen
    Lin, Jiayuh
    CANCER RESEARCH, 2024, 84 (06)
  • [29] Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer
    Zhu, Xiuzhi
    Chen, Li
    Huang, Binhao
    Li, Xiaoguang
    Yang, Liu
    Hu, Xin
    Jiang, Yizhou
    Shao, Zhimin
    Wang, Zhonghua
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2021, 40 (01)
  • [30] Inhibition of ACAA1 Restrains Proliferation and Potentiates the Response to CDK4/6 Inhibitors in Triple-Negative Breast Cancer
    Peng, Wen -Ting
    Jin, Xi
    Xu, Xiao-En
    Yang, Yun-Song
    Ma, Ding
    Shao, Zhi-Ming
    Jiang, Yi-Zhou
    CANCER RESEARCH, 2023, 83 (10) : 1711 - 1724
12345